Actinium Pharmaceuticals, Inc.
Actinium Pharmaceuticals, Inc. (ATNM): 9 pipeline candidates · 2 upcoming catalysts · ~22 mo cash runway · 3 clinical trials. Updated within the last hour.
BioSniper Score
5-factor signal · derived from public data
21.8 months
D/E 18.72 · 0% dilution
Lead: Phase 2/Phase 3
9 candidates
2 upcoming, next in ~10d
N/A
A transparent, data-derived signal for Actinium Pharmaceuticals, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$31.5M
Cash
$42.5M
Quarterly Burn
$5.9M
Runway
21.8 mo
Revenue
—
Cash Runway vs Catalysts
A catalyst falls after projected cash runway — potential financing / dilution risk before it hits.
Pipeline (9 candidates)
| Drug | Phase |
|---|---|
| Actimab-A | Phase 2/Phase 3 |
| Astellas theranostics collaboration | — |
| ATNM-400 | Preclinical |
| Cemiplimab | Phase 1 |
| HER-2 targeting ARC (CD47 combination program) | — |
| HER3 targeting ARC | — |
| Iomab-ACT | Preclinical |
| Iomab-B | Phase 2/Phase 3 |
| Venetoclax | Phase 1 |
Upcoming Catalysts (2)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
Loss of exclusivity — patent/exclusivity expiry opens the door to generic or biosimilar competition that can erode revenue.
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
55
Total value held
$6.0M
| Holder | Shares | Value |
|---|---|---|
| vanguard capital management llc | 2,511,032 | $2.5M |
| millennium management llc | 564,600 | $562K |
| renaissance technologies llc | 471,600 | $469K |
| blackrock, inc. | 371,210 | $369K |
| two sigma investments, lp | 337,168 | $336K |
| geode capital management, llc | 336,073 | $335K |
| gagnon securities llc | 201,300 | $200K |
| vanguard fiduciary trust co | 160,265 | $159K |
| state street corp | 126,215 | $126K |
| susquehanna international group, llp | 123,998 | $123K |
Showing top 10 of 55 institutional holders of Actinium Pharmaceuticals, Inc.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in Actinium Pharmaceuticals, Inc.'s pipeline?
Actinium Pharmaceuticals, Inc. (ATNM) has 9 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Actinium Pharmaceuticals, Inc.'s lead drug candidate?
Actinium Pharmaceuticals, Inc.'s most advanced tracked candidate is Actimab-A (Phase 2/Phase 3) for Acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and solid tumors (HNSCC, NSCLC, GBM, MSI-high colorectal cancer).
What is Actinium Pharmaceuticals, Inc.'s next catalyst?
Actinium Pharmaceuticals, Inc.'s next tracked catalyst is a Phase1_Start event — "Phase 1 Start: A Phase I Trial of 225Ac-anti-CD33 and PD1-Inhibitor in Recurrent Glioblastoma" — expected June 28, 2026.
What is Actinium Pharmaceuticals, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Actinium Pharmaceuticals, Inc. has approximately 21.8 months of cash runway.
What is Actinium Pharmaceuticals, Inc.'s market capitalization?
Actinium Pharmaceuticals, Inc.'s market capitalization is approximately $31.5M.
Get the full picture on Actinium Pharmaceuticals, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.